- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Congress Must Act for Cannabis Patients! Pass Medical Cannabis Legislation NOW! Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2021 State of the States Medical Cannabis Access for Pain Treatment Cannabis and Cannabis Resin- Critical Review Preparation Document Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
What is ASA's IQA Challenge?
Americans for Safe Access’ complaint cites 25 violations under the IQA, alleging that the DEA website currently contains inaccurate statements that do not meet informational standards required by the law. Making matters worse, the DEA continues to distribute statements about the efficacy of medical cannabis and its risks, which have been refuted by the DEA itself in the recent “Denial of Petition to Initiate Proceedings to Reschedule Marijuana,(DPR)” issued August 12, 2016.
In the DPR, the DEA itself made statements that directly contradict information in “The Dangers and Consequences of Marijuana Abuse” and “Drugs of Abuse.” In ASA’s IQA petition, we are calling out the DEA’s own statements, which confirm scientific facts about medical cannabis and analysis, that has long been accepted by a majority of the scientific community. Our request is simple: the DEA must change its public information to better comport with its own expressed views, so that Congress has access to the appropriate tools to make informed decisions about public health.
Elected officials rely on the DEA to provide them fact-based information about medical cannabis to inform policy making. Success in correcting this information will mean politicians can no longer use the misinformation about (1) the gateway drug hypothesis (2) irreversible cognitive decline in adults; and cannabis causing (3) psychosis or (4) lung cancer to deny patients access to medical cannabis.
Was this helpful?